Altavant   Report issue

For profit Phase 2
Founded: Cary NC United States (2018)
Status: Acquired by Sumitomo Dainippon (2019)

Organization Overview

First Clinical Trial
2019
NCT03924154
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Altavant Sciences GmbH | Altavant Sciences, Inc.